{
    "relation": [
        [
            "",
            "Saw Palmetto",
            "Placebo"
        ],
        [
            "Description",
            "One, two, and then three 320 mg gelcaps with dose escalations at 24 and 48 weeks.",
            "One, two, and then three 320 mg placebo gelcaps with dose escalations at 24 and 48 weeks."
        ]
    ],
    "pageTitle": "Complementary and Alternative Medicine for Urological Symptoms(CAMUS) - Study Results - ClinicalTrials.gov",
    "title": "",
    "url": "https://clinicaltrials.gov/ct2/show/results/NCT00603304?sect=X4015&view=results",
    "hasHeader": true,
    "headerPosition": "MIXED",
    "tableType": "RELATION",
    "tableNum": 25,
    "s3Link": "common-crawl/crawl-data/CC-MAIN-2015-32/segments/1438043060830.93/warc/CC-MAIN-20150728002420-00223-ip-10-236-191-2.ec2.internal.warc.gz",
    "recordEndOffset": 869058159,
    "recordOffset": 869041808,
    "tableOrientation": "HORIZONTAL",
    "textBeforeTable": "Reporting Groups No text entered. Significant events and approaches for the overall study following participant enrollment, but prior to group assignment Pre-Assignment Details A total of 1032 men were prescreened for Complementary and Alternative Medicine for Urological Symptoms (CAMUS), usually by telephone; interested and preliminary eligible men were scheduled for a first screening visit. Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations Recruitment Details \u00a0 Hide Participant Flow \u00a0 Participant Flow Drug: Saw Palmetto - first 24 weeks Drug: Placebo - first 24 weeks Drug: Saw Palmetto - weeks 24 - 48 Drug: Placebo - weeks 24 - 48 Drug: Saw Palmetto - weeks 48 - 72 Drug: Placebo - weeks 48 - 72 Interventions: Urological",
    "textAfterTable": "Participant Flow: \u00a0 Overall Study \u00a0 \u00a0 Saw Palmetto \u00a0 \u00a0 Placebo \u00a0 STARTED \u00a0 \u00a0 183 \u00a0 \u00a0 186 \u00a0 COMPLETED \u00a0 \u00a0 151 \u00a0 \u00a0 155 \u00a0 NOT COMPLETED \u00a0 \u00a0 32 \u00a0 \u00a0 31 \u00a0 Lost to Follow-up \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 5 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 7 \u00a0 Withdrawal by Subject \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 8 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 5 \u00a0 Protocol Violation \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 1 \u00a0 \u00a0",
    "hasKeyColumn": true,
    "keyColumnIndex": 0,
    "headerRowIndex": 0
}